Figure 5.

Efficacy of imatinib treatment. Two virtual cohorts, C1 and C2, each with 10⁶ patients, were considered. In all cases, CML dynamics starts from one LSC. Cohort C1 (light green bars) includes only patients with no LSC at diagnosis. Cohort C2 (dark green bars) includes all patients (with and without LSC at diagnosis). (A) Probability of relapse as a function of treatment time. (B) Average log-reduction of disease burden as a function of treatment time. (C) The fraction of C2 patients that reached complete cytogenetic response (CCyR, dark blue) and major molecular response (MMR, cyan). (D) Correlation plot between model prediction of MMR for simulated C2 patients and data for observed MMR for actual patients from Branford et al.³⁶